ReviewClinical medicine (London, England)2025
Metabolic dysfunction-associated steatotic liver disease.
Review in Clinical medicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Integrating MASLD detection into diabetes care in primary care settings in Mexico: A cascade analysis.Clinical medicine (London, England) · 2026Article
- Hepatocyte Models for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comparative Analysis of Non-HepG2 Cell Models.International journal of molecular sciences · 2026Review
- Diagnostic value of serum 25-hydroxyvitamin D, hs-CRP, and adiponectin metabolic dysfunction-associated steatotic liver disease in patients with severe obesity: a retrospective study.American journal of translational research · 2026Article
- Ferroptosis in metabolic dysfunction-associated steatotic liver disease.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly non-alcoholic fatty liver disease (NAFLD), poses a significant challenge to public health. With the rise of obesity, hepatic steatosis now affects around a third of the UK population to varying degrees, frequently coexisting with other cardiometabolic conditions such as type 2 diabetes and ischaemic heart disease. Most patients with MASLD will be diagnosed in the community through investigation of deranged liver function tests or incidentally on abdominal ultrasound. It is therefore important for the general physician to be able to diagnose and risk-stratify MASLD, ensuring appropriate management and onward referral to hepatology for individuals with moderate or high risk of fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.